For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 0 | 677 | 7,679 | - |
| Research and development expenses | 68,262 | 63,897 | 73,809 | 76,619 |
| Change in fair value of contingent consideration liability | 0 | 0 | - | - |
| General and administrative expenses | 12,129 | 13,627 | 18,739 | 19,750 |
| Total operating expenses | 80,391 | 77,524 | 92,548 | 96,369 |
| Loss from operations | -80,391 | -76,847 | -84,869 | -96,369 |
| Interest income | 6,407 | 7,105 | 7,813 | 8,274 |
| Other (expense) income | -165 | -633 | -9 | -10 |
| Total other income, net | 6,242 | 6,472 | 7,804 | 8,264 |
| Net loss | -74,149 | -70,375 | -77,065 | -88,105 |
| Unrealized holding gain | 656 | -201 | 1,029 | 3,849 |
| Total other comprehensive income | 656 | -201 | 1,029 | 3,849 |
| Total comprehensive loss | -73,493 | -70,576 | -76,036 | -84,256 |
| Net loss per share, basic | -0.43 | -0.41 | -0.46 | -0.63 |
| Net loss per share, diluted | -0.43 | -0.41 | -0.46 | -0.63 |
| Weighted average shares of common stock, basic | 172,389,209 | 171,264,622 | 169,233,155 | 140,229,056 |
Relay Therapeutics, Inc. (RLAY)
Relay Therapeutics, Inc. (RLAY)